IXICO – full-year results, “a strong financial performance”?

Most recently on company describing itself as “a global leader in neuroscience imaging and biomarker analytics” IXICO (IXI), I wrote ‘has it been attempted ramptastic ahead of upcoming results?’. So what of now its results for its year ended 30th September 2025 emphasising “Execution of the group’s Innovate Lead Scale strategy across the year has delivered a strong financial performance with 13% revenue growth and a 21% reduction in EBITDA loss. Commercial traction has further accelerated into FY26, resulting in a 27% increase to the order book since the FY25 year-end”?

IXICO – “Operational Update”, has it been attempted ramptastic ahead of upcoming results?

Describing itself as “a global leader in neuroscience imaging and biomarker analytics”, IXICO (IXI) has issued an “Operational Update” after last month a “Clinical Trial Contract Win” and on 30th October a 'Capital Markets Day'. What about those ahead of 9th December-scheduled results?

IXICO – full-year results, how much is recent fundraising to ‘accelerate technology platform growth and global commercial reach’?

Describing itself as “a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders”, IXICO (IXI) has announced results for its year ended 30th September 2024 and emphasises “the appointment of Bram Goorden as CEO towards the end of H2, the completion of an oversubscribed £4 million capital raise in October, and the launch of the group's next generation TrialTracker AI-driven imaging platform, underpinned by growth in the group's orderbook towards the end of the year”. So what of a current share price response more than 10% lower to 11p?

IXICO – fundraising, how much really to ‘accelerate technology platform growth and global commercial reach’?

Medical imaging analytics company IXICO (IXI) states that it “is pleased to announce that it has conditionally raised gross proceeds of £4.0 million… The issue price of 9.5 pence represents a premium of 5.6 per cent to the closing middle market price of 9.0 pence per ordinary share on 7 October 2024, being the last business day prior to the announcement of the fundraising”. How’s the outlook then now from a current 9.25p share price?

IXICO (#IXI) – £4m placing and subscription at 9.5p per share and a “retail offer”

IXICO – “expected to be ahead of market expectations”, but still how adequate are the financial resources?

Medical imaging analytics company IXICO (IXI) has announced a “delighted to be awarded” contract and a trading “expected to be ahead of market expectations” update. What of the shares responding to those currently up to 9.5p?

IXICO (#IXI) – expects FY “ahead of market expectations”, but that was even EBITDA loss and revenue set to still be below prior year

IXICO – “delighted to welcome” new CEO, but how “adequate” are the “financial resources” now?

Medical analytics company IXICO (IXI) is “delighted to welcome Bram (Goorden) to the board as our CEO… as IXICO looks to return to growth, Bram's experiences provide excellent credentials to ensure IXICO also realises shareholder value”. So what of this and the shares responding up to 7.125p?

IXICO – announces another “contract win”, but how’s the balance sheet now?

Medical analytics company IXICO (IXI) has issued a “Contract Win” announcement including that it “is pleased to announce that it has been contracted by a top five CRO on behalf of a new pharma client… win valued in excess of £1m”. What of the detail and a share price response currently more than 12% higher to 7.25p?

IXICO – contract win & interims, how ‘confident’ to be that it has “adequate financial resources… for the foreseeable future”?

Describing itself as a “medical imaging advanced analytics company delivering insights in neuroscience”, IXICO (XI) has issued a “Contract Win” announcement emphasising “the contract value is worth over £1 million over a 48-month term”. Though what does that mean from a current 7.25p share price?

IXICO – trading warning, prior revenue guidance that now dare not speak its name!

Previously writing on medical analytics company IXICO plc (IXI), just over a year ago with the shares up to 26.5p I was cautious noting trading and bottom-line concerns. So what of today a “Trading Update” and the shares further lower from an 8.5p most recent close?

IXICO – next year “expects to achieve double digit revenue growth”, but what about this year and the bottom-line?

Medical analytics company IXICO plc (IXI) has issued a trading update commencing that it “reconfirms its revenue expectations of £7 million for the year to 30 September 2023 and announces that it now expects to achieve double digit revenue growth in the year to 30 September 2024”. So what of this currently helping the shares up to 26.5p?

IXICO – “contract win”. Is it?, and what about the contract loss and financial outlook?

Medical analytics company IXICO plc (IXI) has announced that it “has been selected by a leading global pharmaceutical company, and new client, to provide MRI imaging services for an early phase clinical trial”. So what’s the detail, with the shares currently up approaching 4% at 26.5p in response?

IXICO – “a strong set of financial results”, Really?

Medical analytics company IXICO plc (IXI) has announced what it emphasises as “a strong set of financial results… strong balance sheet supports the execution of our renewed five-year strategic plan”. So what of a share price response currently approaching 6% lower at 27.5p, to give a £13.2 million market cap?

IXICO (#IXI) – expects FY EBITDA to “comfortably exceed previous guidance of £1.2 million”. What about the bottom-line though?

IXICO – ahead of expectations, but set not to be so for long...

Medical analytics company IXICO plc (IXI) has announced results for its half-year ended 31st March 2022, including that it now anticipates that it will “materially exceed” market profit expectations for the full year. So what of a current 37.5p share price, down more than 9%?!...

IXICO – contract award, but how’s the cash burn?...

Biopharmaceutical data analytics company IXICO (IXI) has announced it has been selected for an open-label Phase I/II dose finding study, emphasising it “reflects the confidence of our clients in the use of our services”. So what of a share price slightly ahead to 43.5p, but comparing to 58.5p in December?...

IXICO – full-year results, ‘resilience built in’?

Biopharmaceutical data analytics company IXICO (IXI) has announced results for its year ended 30th September 2021 and the shares are currently more than 16% higher to 58.5p. However that compares to circa 84.5p when I previously wrote in October, so what’s the story now?...

IXICO – emphasises “ahead of market expectations”, but what does that mean financially and what’s to come?...

Biopharmaceutical data analytics company IXICO (IXI) has made a trading update including that year ended 30th September 2021 EBITDA is “expected to be materially ahead of market expectations of £1.2 million and prior year (2020: £1.3 million)”. Why then is the share price little changed at circa 84.5p?...

IXICO (#IXI) – FY update, one-offs & investment to hinder bottom-line this year